Sublingual GLP-1 Formulation for Improved Peptide Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 receptor agonists (GLP-1 RA-Ps) for treating type 2 diabetes and obesity are primarily administered via subcutaneous injection, which is inconvenient for many patients, and existing oral formulations like Rybelsus have low bioavailability and require optimal conditions for absorption.
Innovation Solution
Development of a pharmaceutical formulation for sublingual administration of GLP-1 RA-Ps, such as TE-8105, semaglutide, and tirzepatide, in a buffer solution with pH 5.5 to 7.5, achieving 2-10% bioavailability, available in liquid, tablet, or soft gel forms, to facilitate needle-free delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subcutaneous injection is used for GLP-1 RA-Ps, then therapeutic effectiveness is achieved, but patient convenience and compliance deteriorate due to needle fear and inconvenience
Solution Approach 1:
The patent replaces the mechanical injection system (needles, syringes, subcutaneous delivery) with a sublingual mucoadhesive formulation that utilizes the natural mucosal surface of the mouth for drug delivery. This substitution eliminates the need for mechanical needles while maintaining therapeutic effectiveness through direct mucosal absorption of the GLP-1 RA-P peptide.
Solution Approach 2:
The patent introduces a mucoadhesive polymer formulation as an intermediary carrier that facilitates peptide delivery across the sublingual mucosa. This intermediary system enables the peptide to cross the biological membrane without requiring injection, thereby improving patient convenience while maintaining therapeutic reliability.
2Ease of operation
If oral formulation (Rybelsus) is used for GLP-1 RA-Ps, then needle-free delivery is achieved, but bioavailability deteriorates to about 0.1-1% and requires optimal absorption conditions
Solution Approach 1:
The patent employs a mucoadhesive polymer as an intermediary that enhances peptide absorption across the sublingual mucosa. This formulation mechanism directly addresses the low bioavailability issue by facilitating more efficient peptide transport, achieving significantly higher bioavailability than conventional oral tablets while maintaining needle-free delivery.
Solution Approach 2:
The patent changes the delivery parameters from conventional oral (swallowed) to sublingual (mucosal absorption), and modifies the formulation parameters by incorporating mucoadhesive polymers with specific molecular weights and concentrations. These parameter changes enable dramatically improved bioavailability while maintaining the convenience of needle-free administration.
3Ease of manufacture
If conventional oral tablet formulation is used, then manufacturing simplicity is maintained, but absorption efficiency and bioavailability deteriorate
Solution Approach 1:
The patent creates a composite formulation combining the GLP-1 RA-P peptide with mucoadhesive polymers in a specific ratio (peptide:polymer weight ratio). This composite material approach maintains manufacturing simplicity while dramatically improving absorption efficiency through the synergistic interaction between the peptide and mucoadhesive polymer components.
Solution Approach 2:
The patent optimizes formulation parameters including polymer concentration (0.1-10% w/v), peptide-to-polymer ratio, and molecular weight selection. These parameter optimizations enable the formulation to maintain ease of manufacture while achieving superior absorption efficiency and bioavailability compared to conventional tablets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sublingual formulation effectively lowers blood glucose levels and reduces body weight in diabetic and obese animal models, offering a convenient and more effective alternative to traditional injection methods.
Implementation Method 1
achieve a bioavailability of about 2-10% of the GLP-1 RA-P compared to a subcutaneous injection
Data Source
AI summary
Disclosed herein are formulations suitable for sublingual administration in the treatment of obesity, type II diabetes, or disorders related thereto. The formulation includes 5-10 mg of a glucagon-like peptide-1 receptor agonist peptide (GLP-1 RA-P) dissolved in 1.5-2.0 mL of a buffer solution, and a pH value of about 5.5 to 7.5. Also disclosed herein are methods for treating obesity, type II diabetes, or disorders related thereto. The method includes sublingually administering the present formulation to the subject and keeping the formulation under the tongue of the subject for 5 to 10 minutes, wherein the sublingual administration of the formulation achieves 2-10% bioavailability of the GLP-1 RA-P as compared to that achieved by subcutaneous injection.